Status:
COMPLETED
Prostate Accurately Targeted Radiotherapy Investigation of Overall Treatment Time
Lead Sponsor:
CancerCare Manitoba
Collaborating Sponsors:
Sunnybrook Health Sciences Centre
British Columbia Cancer Agency
Conditions:
Prostatic Neoplasms
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to compare the toxicity of two new radiation schedules for the treatment of prostate cancer. Patients will be randomized to receive 5 treatments delivered every other day ...
Eligibility Criteria
Inclusion
- Low or intermediate risk prostate cancer patients as defined by:
- Clinical stage T1-2b, Gleason Score \<=7, and PSA \<=20 ng/mL
- Age \>= 18 years
Exclusion
- Androgen deprivation therapy (LHRH-agonists or antiandrogens) \>6 months
- Prior pelvic radiotherapy
- Anticoagulation medication (if unsafe to discontinue for gold seed insertion)
- Diagnosis of bleeding diathesis
- Large prostate (\>90cm3) on imaging
- Immunosuppressive medications
- Inflammatory bowel disease
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2019
Estimated Enrollment :
152 Patients enrolled
Trial Details
Trial ID
NCT01423474
Start Date
January 1 2012
End Date
August 1 2019
Last Update
February 23 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
BC Cancer Agency - Abbotsford Centre
Abbotsford, British Columbia, Canada, V2S 0C2
2
CancerCare Manitoba
Winnipeg, Manitoba, Canada, R3E 0V9
3
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5